Babies use their immune system differently but efficiently

Scientists have long believed that a newborn’s immune system was an immature version of an adult’s, but new research shows that newborns’ T cells – white blood cells that protect from disease – outperform those of adults at fighting off numerous infections.

New grants support student involvement in community projects

Faculty, staff and community partners are working together to address community needs — and they’re getting students involved with support from Engaged Opportunity Grants from the Einhorn Center for Community Engagement.

Around Cornell

New insight into old IBD drug could improve treatments

Weill Cornell researchers find inflammatory bowel disease drug works by modulating the activity of a group of gut bacteria that are more abundant in patients who respond to the drug.

Let’s Meditate celebrates 10 years of campus mindfulness

Open to the entire Cornell community, the meditation program serves to counter the rigor of classes and work, offering participants a moment to breathe and reflect via sessions offered both in-person and virtually.

Surveillance surveys give clearer picture of COVID’s spread

Door-to-door surveillance surveys can provide more precise estimates of how many people are infected with COVID-19 or have immunity to COVID-19 at any given point in time than relying on self-reporting and self-testing, a Cornell-led research group has found.

Mycologist, synthetic biologist win 2024 Schwartz research awards

Two faculty members – one studying killer fungi and the other using yeast to find safer painkillers – are winners of Schwartz grants, given annually to female faculty or faculty who enhance the diversity, equity and inclusion goals of the university.

Vaccine shows promise against CMV, a virus that causes birth defects

An experimental mRNA vaccine against human cytomegalovirus, a common virus that can infect babies during pregnancy, elicited some of the most promising immune responses to date of any vaccine candidate, according to a study by Weill Cornell Medicine investigators.

Apixaban no better than aspirin for preventing some strokes

A multicenter, phase 3 clinical trial has found that apixaban is no more effective than aspirin at preventing a second stroke in patients diagnosed with a milder, related condition called atrial cardiopathy, according to new research.